Press Resease

Basal Cell Carcinoma Treatment Market - Global Industry Analysis

Basal Cell Carcinoma Treatment Market by Treatment Type (Surgery, Drugs, and Others) and by End-user (Hospitals, Specialty Clinics, and Other End Users): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024

Published Date: 28-Aug-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3297 Status : Published

Global basal cell carcinoma market expected to generate revenue of around USD 9789.6 million by end of 2024, growing at a CAGR of around 8.9% between 2018 and 2024. Basal cell carcinoma market is mainly driven by the increased prevalence of various skin diseases such as melanoma and others.

Description

The report covers forecast and analysis for the basal cell carcinoma market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the basal cell carcinoma market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the basal cell carcinoma market on a global level.

In order to give the users of this report a comprehensive view of the basal cell carcinoma market, we have included competitive landscape and analysis of Porter’s Five Forces model in the market. The study encompasses a market attractiveness analysis, where treatment, end use, and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.

Global Basal Cell Carcinoma Treatment Market

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments in the market, including acquisitions & mergers, new treatment launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved on the market on the global and regional basis. 

The study provides a decisive view of the basal cell carcinoma market by segmenting the market based on treatment type, end user, and regions. All the segments have been analyzed based on present and future trends and the market are estimated from 2018 to 2024. 

Based on treatment type, the basal cell carcinoma market is segmented as surgery, drugs, and others. Based on the end user, the basal cell carcinoma market is segmented as hospitals, specialty clinic, and others. 

Increased prevalence of skin disorders is one of the major driving factors of Basal Cell Carcinoma Market. Increased awareness coupled with favorable reimbursement policies are expected to drive the growth of basal cell carcinoma market. However, the high cost of treatment and high susceptibility of basal cell carcinoma to remain under diagnosed are the factors that influence the market growth during the forecast period.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries, including the U.S., Germany, France, UK, China, Japan, India, and Brazil. This segment includes demand for Basal Cell Carcinoma Market based on individual segment and treatment in all the regions and countries.

The report also includes detailed profiles of end players such as Merck & Co. Inc., Valeant Pharmaceuticals International Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., Sun Pharmaceuticals Ltd., Allergan, Inc., Allergan, Inc., Perrigo Company plc, Strides Arcolab Ltd., and others. 

This report segments the global basal cell carcinoma market as follows:

Global Basal Cell Carcinoma Treatment Market: Treatment Type  Analysis

  • Surgery
  • Drugs
  • Others

Global Basal Cell Carcinoma Treatment Market: End User Analysis

  • Hospitals
  • Specialty Clinics
  • Others

Global Basal Cell Carcinoma Treatment Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Basal Cell Carcinoma Treatment Market, 2015 - 2024 (USD Billion)
    • 2.2. Global Basal Cell Carcinoma Treatment Market: Snapshot
  •  
  • Chapter 3. Basal Cell Carcinoma Treatment Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Basal Cell Carcinoma Treatment Market drivers: Impact analysis
      • 3.2.2. Increased prevalence of skin disorders
    • 3.3. Market restraints
      • 3.3.1. High cost of treatment
      • 3.3.2. High susceptibility of basal cell carcinoma to remain under diagnosed
    • 3.4. Opportunities
      • 3.4.1. Increasing demand of better treatment in emerging economies
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Treatment Type
      • 3.6.2. Market attractiveness analysis, by End User
      • 3.6.3. Market attractiveness analysis, by Regional Segment
  •  
  • Chapter 4. Global Basal Cell Carcinoma Treatment Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Basal Cell Carcinoma Treatment Market: company market share, 2015
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Treatment Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  •  
  • Chapter 5. Global Basal Cell Carcinoma Treatment Market - Treatment Segment Analysis
    • 5.1. Global Basal Cell Carcinoma Treatment Market: Treatment overview
      • 5.1.1. Global Basal Cell Carcinoma Treatment Market revenue share, by Treatment, 2015 and 2024(USD Billion)
    • 5.2. Surgery
      • 5.2.1. Global Surgery market, 2015 - 2024(USD Billion)
    • 5.3. Drugs
      • 5.3.1. Global Drugs Therapy market, 2015 - 2024(USD Billion)
    • 5.4. Others
      • 5.4.1. Global Others market, 2015 - 2024(USD Billion)
  •  
  • Chapter 6. Global Basal Cell Carcinoma Treatment Market - End User Segment Analysis
    • 6.1. Global Basal Cell Carcinoma Treatment Market: End User overview
      • 6.1.1. Global Basal Cell Carcinoma Treatment Market revenue share, by End User , 2014 and 2024(USD Billion)
    • 6.2. Hospitals
      • 6.2.1. Global Basal Cell Carcinoma Treatment Market for Hospitals, 2015 - 2024(USD Billion)
    • 6.3. Specialty Clinics
      • 6.3.1. Global Basal Cell Carcinoma Treatment Market for Specialty Clinics, 2015 - 2024(USD Billion)
    • 6.4. Others
      • 6.4.1. Global Basal Cell Carcinoma Treatment Market for Others, 2015 - 2024(USD Billion)
  •  
  • Chapter 7. Global Basal Cell Carcinoma Treatment Market - Regional Segment Analysis
    • 7.1. Global Basal Cell Carcinoma Treatment Market: Regional overview
      • 7.1.1. Global Basal Cell Carcinoma Treatment Market revenue share, by Region, 2015 and 2024
    • 7.2. North America
      • 7.2.1. North America Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 7.2.2. North America Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
      • 7.2.3. North America Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.2.4. U.S.
        • 7.2.4.1. U.S. Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.2.4.2. U.S. Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.2.4.3. U.S. Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.2.5.2. Rest of North America Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.2.5.3. Rest of North America Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 7.3.2. Europe Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
      • 7.3.3. Europe Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.3.4. Germany
        • 7.3.4.1. Germany Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.3.4.2. Germany Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.3.4.3. Germany Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.3.5. U.K.
        • 7.3.5.1. U.K. Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.3.5.2. U.K. Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.3.5.3. U.K. Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.3.6. France
        • 7.3.6.1. France Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.3.6.2. France Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.3.6.3. France Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.3.7. Rest of Europe
        • 7.3.7.1. Rest of Europe Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.3.7.2. Rest of Europe Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.3.7.3. Rest of Europe Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 7.4.2. Asia Pacific Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
      • 7.4.3. Asia Pacific Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.4.4. China
        • 7.4.4.1. China Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.4.4.2. China Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.4.4.3. China Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.4.5. Japan
        • 7.4.5.1. Japan Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.4.5.2. Japan Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.4.5.3. Japan Basal Cell Carcinoma Treatment Market revenue, by region, 2015 - 2024(USD Billion)
      • 7.4.6. India
        • 7.4.6.1. India Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.4.6.2. India Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.4.6.3. India Basal Cell Carcinoma Treatment Market revenue, by region, 2015 - 2024(USD Billion)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.4.7.2. Rest of Asia Pacific Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.4.7.3. Rest of Asia Pacific Basal Cell Carcinoma Treatment Market revenue, by region, 2015 - 2024(USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 7.5.2. Latin America Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
      • 7.5.3. Latin America Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.5.4.2. Brazil Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.5.4.3. Brazil Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
      • 7.5.5. Rest of Latin America
        • 7.5.5.1. Rest of Latin America Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 7.5.5.2. Rest of Latin America Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
        • 7.5.5.3. Rest of Latin America Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa Basal Cell Carcinoma Treatment Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 7.6.2. Middle East and Africa Basal Cell Carcinoma Treatment Market revenue, by End User , 2015 - 2024(USD Billion)
      • 7.6.3. Middle East and Africa Basal Cell Carcinoma Treatment Market revenue, by Region, 2015 - 2024(USD Billion)
  •  
  • Chapter 8. Company Profile
    • 8.1. Merck & Co. Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Valeant Pharmaceuticals International Inc.
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. F. Hoffmann-La Roche Ltd.
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Mylan N.V.,
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Sun Pharmaceuticals Ltd.
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Allergan, Inc.
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Perrigo Company plc
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Strides Arcolab Ltd.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments

Methodology

Free Analysis

Basal cell carcinoma is a type of nonmelanocytic cancer that arises from basal cells present in the lower epidermis. It does not spread to other parts of the body but in rare cases, it can metastasize to other body parts and it is generally caused by the exposure to ultraviolet rays. Immunosuppressant drugs are further expected to increase the probability of basal cell carcinoma as the immune system is suppressed by these drugs. Basal cell carcinoma can be life-threatening in rare conditions and white people are considered more vulnerable to basal cell carcinoma. The symptom for basal cell carcinoma includes waxy papules with a central depression and bleeding can also be observed from those papules. There are various treatment options available for the basal cell carcinoma such as surgery, drugs, and others such as radiation therapy and it may take some time to get completely cured.

The major factors driving the growth of basal cell carcinoma treatment market over the forecast period are an increase in various types of skin disorders coupled with melanoma and others. Increased prevalence of cutaneous malignancies is further expected to drive the growth of basal cell carcinoma treatment market. As per the American Cancer Society 2018 report, an estimated 91,270 adults (55,150 men and 36,120 women) in the United States were diagnosed with melanoma of the skin. Melanoma is the fifth most common cancer among men and the sixth most common cancer in women. Australia is expected to have a number of cases for basal cell carcinoma as compared to other countries. Furthermore, increase in geriatric population, increased prevalence, and favorable reimbursement policies are further expected to support the growth of basal cell carcinoma treatment market.

Global Basal Cell Carcinoma Treatment Market

Basal cell carcinoma treatment market is segmented on the basis of treatment type, end-user, and region. Treatment type segment is further classified into surgery, drugs, and others. Surgery segment is expected to grow rapidly over the forecast period. Based on the end user, the market is segmented into hospitals, specialty clinics, and others. Hospitals and specialty clinics are expected to grow significantly in the near future.

Basal cell carcinoma treatment is regionally segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to contribute to the major market share which is expected to be closely followed by Europe over the forecast period. The major contribution of these regions is due to the advanced medical and healthcare facilities and infrastructure. The Asia Pacific is expected to grow moderately over the forecast period. Latin America and the Middle East and Africa are expected to develop at a considerable rate within the forecast period.

Some of the key players of basal cell carcinoma treatment market include Merck & Co. Inc., Valeant Pharmaceuticals International Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., Sun Pharmaceuticals Ltd., Allergan, Inc., Perrigo Company plc, and Strides Arcolab Ltd., amongst others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social